The Alexandria Venture Investments-backed genetic disease therapy developer is floating above its range having increased the number of shares in the offering.

US-based genetic disease drug developer Stoke Therapeutics will raise approximately $142m when it floats later today, providing an exit for life sciences real estate investment trust Alexandria Real Estate Equities. The company priced its shares at $18.00 each, above the IPO’s $14 to $16 range. It also increased the number of shares from 6.7 million…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.